deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02314052

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Conditions Hepatocellular Carcinoma
Interventions DCR-MYC
Updated 12 times since 2017 Last updated: Jul 10, 2024 Started: Jan 27, 2015 Primary completion: Oct 11, 2016 Completion: Oct 11, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

Other terminated trials from Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

See all terminations from Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

Listed as NCT02314052, this PHASE1/PHASE2 trial focuses on Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, it has been updated 12 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshotActive Not Recruiting~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshotTerminated~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotTerminated~Oct 2018 – ~Jan 2021 · 27 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~May 2023 · 17 months · monthly snapshotTerminated~May 2023 – ~Jul 2024 · 14 months · monthly snapshotTerminated~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshotTerminated~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

  4. Jul 2024 — Aug 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. May 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 7 earlier versions

  1. Dec 2021 — May 2023 [monthly]

    Terminated PHASE1_PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

  3. Oct 2018 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  4. Jun 2018 — Oct 2018 [monthly]

    Terminated PHASE1_PHASE2

  5. Aug 2017 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  6. Feb 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations